Reach announcement (non-regulatory)*

5 November 2021

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Proteome Sciences and INmune Bio to present biomarker discovery data at Clinical Trials in Alzheimer's Disease 2021, Boston

November 5^th 2021 - London, UK & Boca Raton, USA - Proteome Sciences announces that Dr. Ian Pike, Chief Scientific Officer of Proteome Sciences, will be presenting data from a recent study performed with INmune Bio of Boca Raton, Florida, at the 2021 edition of Clinical Trials in Alzheimer's Disease conference being held in Boston, USA from November 7^th to 9^th. In this study, Proteome Sciences used its patented TMTcalibrator™ workflow to discover biomarkers supporting the response of Alzheimer's disease patients enrolled in a Phase I clinical study of INmune Bio's XPro1595.

Xpro1595 is a novel sTNF antagonist targeting inflammation and related processes associated with Alzheimer's disease and other neurodegenerative conditions. A recently completed Phase I trial showed promising results, including evidence of reduced inflammation and re-myelination in brain white matter obtained through imaging studies. To further support decisions for future clinical studies, INmune Bio contracted Proteome Sciences to deliver an in-depth proteomics analysis of cerebrospinal fluid samples.

This analysis discovered multiple peripheral biomarkers consistent with anti-inflammatory action, as well as pathways related to neurodegeneration, neuronal organization, synaptic function and myelination. Most strikingly, it revealed a broad reduction in the phosphorylation of tau protein, which is a common hallmark of Alzheimer's disease, and in particular at the pT217 site which has recently been reported as an important biomarker with strongly increased levels seen in advanced disease. Several of these proteins may be developed for monitoring progression in Phase II clinical studies.

Dr. RJ Tesi, CEO, INmune Bio commented "The use of biomarkers to drive clinical development forward in CNS diseases including Alzheimer's disease may be a key to success. The use of Proteome Science's TMTcalibrator™ in CSF of patients treated with XPro has given us new insights into Alzheimer's disease and the effects of XPro therapy."

Dr. Ian Pike said "We are delighted that INmune Bio has joined the growing list of customers recognizing the value of our TMTcalibrator™ workflow. The novel combination of diseased tissue with peripheral fluids provides a much deeper and more relevant mapping of biomarkers with utility for strengthening analysis of clinical trial data. We are notably able to profile changes in tau phosphorylation at over 30 sites with very high sensitivity to changes, whilst also covering expression of over 3,500 other proteins. In the short-term, proteomics data can help guide selection of dose and treatment regime for future studies, whilst also providing more readily implemented biomarkers. Longer-term, these biomarkers can be developed for use in the routine clinical management of Alzheimer's disease patients."

End.

For further information:

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

*About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as a regulatory announcement via RNS and not on Reach.